Graphical Abstract Highlights d Mast1 associates with the microtubule cytoskeleton in a MAP-dependent manner d Mast1 is expressed in postmitotic neurons but not neuronal progenitors d Mast1 Leu278del mice have an enlarged corpus callosum and smaller cerebellum d More axons cross the midline in Mast1 Leu278del mice despite cortical apoptosis SUMMARY
Correspondence
In Brief Tripathy et al. show that mutations in MAST1, a microtubule-associated protein, cause a syndrome characterized by an enlarged corpus callosum. They attribute this thickening to an increase in the number of contralateral projections despite extensive cortical apoptosis. are phenotypically normal, whereas the deletion of a single amino acid (L278del) recapitulates the distinct neurological phenotype observed in patients. In animals harboring Mast1 microdeletions, we find that the PI3K/AKT3/mTOR pathway is unperturbed, whereas Mast2 and Mast3 levels are diminished, indicative of a dominant-negative mode of action. Finally, we report that de novo MAST1 substitutions are present in patients with autism and microcephaly, raising the prospect that mutations in this gene give rise to a spectrum of neurodevelopmental diseases. , and, in the more severely affected, mildly thick cortex (G and J; thus consistent with mild lissencephaly). While diffused, the cortical malformation appears most severe in the posterior frontal and perisylvian regions. The lateral ventricles are mildly to moderately enlarged, and the corpus callosum is abnormally thick (arrows in A, E, I, K, M, and Q), accompanied by mildly thick white matter. The brainstem, especially the pons, is mildly (E) or moderately (A, I, K, M, and Q) small, and in at least one child a prominent ventral midline cleft of the pons is seen (arrow in N). Available axial images through the high convexity of the cerebral hemispheres showed very dysplastic, longitudinally oriented gyral pattern (long arrows in D, H, and P).
(legend continued on next page)
INTRODUCTION
The bilateral integration of sensory, motor, and cognitive inputs is mediated by the corpus callosum, the largest white matter tract of the brain (Paul et al., 2007) . A broad array of neurodevelopmental disorders are known to be associated with malformations of this structure. For instance, corpus callosum agenesis has been reported in patients with microcephaly, lissencephaly, and polymicrogyria and has been described in patients with autism (Parrini et al., 2016) . Mouse and human genetics studies have provided insight into the molecular machinery that is required for the development of this important anatomical feature (Edwards et al., 2014) . It has been shown that the midline crossing of post-mitotic neurons requires transcription factors such as Satb2 (Britanova et al., 2008) , cell adhesion molecules such as L1-CAM (Demyanenko et al., 1999) , guidance molecules such as Netrin1 and the semaphorins (Niquille et al., 2009; Serafini et al., 1996) , and cytoskeletal proteins including Map1b and the b-tubulin Tubb3 (Meixner et al., 2000; Tischfield et al., 2010) . Collectively, these molecules specify the fate of neurons destined to traverse the cerebral hemispheres, guiding their leading process to the correct destination. While thinning of the corpus callosum is relatively common, in rare instances patients present with a thickening of this myelinated structure (Edwards et al., 2014; Marsh et al., 2017) . To date, this phenotype has been reported in patients with neurofibromatosis and megalencephaly-polymicrogyria-mega-corpuscallosum syndrome (DiMario et al., 1999; Gö hlich-Ratmann et al., 1998) . These diseases are associated with a generalized enlargement in brain size, driven by activation of the PI3K/ AKT3/mTOR pathway attributable to mutations in PIK3R2 and NF1 (Johannessen et al., 2005; Nguyen et al., 2016; Terrone et al., 2016) . As mutations in these genes do not account for all cases, it is apparent that our understanding of the molecular pathology that underlies mega-corpus-callosum syndromes is incomplete (Hengst et al., 2010) . Here, we present a cohort of patients with an enlarged corpus callosum in the absence of megalencephaly, harboring mutations in the uncharacterized microtubule-associated protein (MAP) MAST1.
RESULTS

Identification of MAST1 Mutations
As part of an ongoing endeavor to identify genetic variants associated with structural brain malformations, we undertook wholeexome sequencing on 7 patient-parent trios where the affected individual presented with a striking enlargement of the corpus callosum. This led to the identification of de novo mutations in the gene MAST1 (microtubule-associated serine threonine kinase 1) in 6 of the 7 affected individuals ( Figures 1A-1T ). Each of these patients presented with a hyperplastic corpus callosum (particularly over the genu and mid-body), cerebellar hypoplasia, ventricular dilation, and impaired motor and verbal performance (Table 1) . Four patients presented with gyral simplification (P2 [Pierson et al., 2008] , P3, P5, P6), three with dysplastic longitudinal gyri (P1, P5, P6), and one (P4) with periventricular nodules of white matter. We refer to this syndrome as mega-corpus-callosum with cerebellar hypoplasia and cortical malformations (MCC-CH-CM).
Through the Genematcher platform, four additional patients with de novo mutations in MAST1 were identified who presented with either microcephaly accompanied by motor deficits (P7, P8) or autism spectrum disorder (P9, P10) (Figures S1A-S1E, Table S1 ) (Gilissen et al., 2014; Sobreira et al., 2015) . In each case the mutation was verified by Sanger sequencing, was unreported in publicly available genome databases (e.g., dbSNP, 1000 genome, ExAC; see Table S2 ), and was in a highly conserved residue (Figures S1F-S1L) that was predicted to be deleterious when mutated (Table 1, Table S1 , CADD score) (Kircher et al., 2014; Lek et al., 2016) . We did not identify any unreported variants in our patient cohort, with the exception of a silent mutation in TUBGCP5 (T457T) in P2 and a de novo mutation in NIMA related kinase 1 (NEK1) in P8 (Table 1, Table S1 ). It should be noted that mutations in NEK1 have been previously associated with amyotrophic lateral sclerosis, cilial dysfunction, and skeletal diseases; however, patient P8 did not present with symptoms consistent with these disorders (Kenna et al., 2016; Thiel et al., 2011) . Three of the MCC-CH-CM-associated variants in MAST1 were single amino acid deletions positioned in the hydrophobic core of a four-helix bundle in the domain of unknown function DUF1908 (P1, p.Glu194del; P2, p.Lys276del; P3, p.Leu278del) ( Figure S1M ), while the remainder (P4-P6, p.Gly517Ser) harbored a recurrent missense mutation in the kinase domain of the protein (Figures 1U and 1V) . These microdeletions were not found in control individuals in the ExAC genome browser; however, a single microdeletion between the kinase and PDZ domains (Glu697del) has been reported (Table S2) .
MAST1 Is a Microtubule-Associated Protein
Little is known of the function of the MAST family of proteins (MAST1-4). MAST2 was initially cloned from testes and was (U) Schematic representation of the MAST1 genomic locus shows the position of the mutations identified in patients P1-P6. (V) The MAST1 protein consists of a domain of unknown function (DUF1908, shown in red), a kinase domain (shown in yellow), and a PDZ domain (shown in blue). The amino acid boundaries of each of the domains are shown. (W-Z) Autoradiograph showing the results of the microtubule binding assay with Mast1. Murine Mast1 was radiolabeled ( 35 S) by in vitro transcription and translation (TnT) in rabbit reticulocyte lysate, before incubation with a porcine microtubule extract in the presence or absence of microtubule-associated proteins (MAPs) (W and X). Following microtubule polymerization in the presence of Taxol, pelleted microtubules were analyzed by polyacrylamide gel electrophoresis (PAGE), and the ratio of pelleted radiolabeled-mMast1 to TnT input was determined. This experiment revealed a decrease of binding of Mast1 to microtubules in the absence of MAPs (X; n = 6 technical replicates; two-tailed unpaired t test; t7 = 7.134, p < 0.0001). Patient mutations were introduced into mMast1, radiolabeled by in vitro TnT, and microtubule binding was assessed (Y and Z). The ratio of microtubule-bound Mast1 (in the pelleted fraction) to TnT input was determined. Comparison of pelleted wild-type Mast1 to the K276del mutation shows a significant alteration in microtubule binding and a similar trend for the L278del (Z; n = 6-9 repeated experiments; one-way ANOVA with Dunnett's multiple comparison; WT versus K276del p < 0.05). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Error bars show mean ± SEM. shown to function as a kinase and interact with microtubules via other MAPs (Walden and Cowan, 1993) . To ascertain whether MAST1 associates with the microtubule cytoskeleton, we performed an in vitro transcription and translation (TnT) reaction employing rabbit reticulocyte lysate with radiolabeled murine (m) Mast1 (which shares 94% sequence identity with human MAST1). The reaction products were then assayed for their ability to bind to microtubules in the absence or presence of MAPs. We found that mMast1 associates with Taxol-stabilized microtubules in a MAP-dependent manner (Figures 1W and 1X; n = 6; p < 0.0001). Next, we asked whether the MAST1 mutations found in our patient cohort influence microtubule binding. We introduced each mutation into our pcDNA 3.1 vector, labeled Mast1 with 35 S-methionine, and repeated the aforementioned microtubule binding assay. While translation efficiency was similar for all variants, we found that the K276 deletion significantly enhanced Mast1 binding to microtubules (Figures 1Y and 1Z; n = 9; WT versus K276del p < 0.05). Taken together, these data show that Mast1 binds to microtubules in a MAP-dependent manner and that mutations can perturb this interaction.
MAST1 Is Expressed in Post-mitotic Neurons
To gain insight into the role of MAST1 in neurodevelopment, we analyzed its expression in the human and mouse brain during early developmental stages (Figures 2A and 2B ). To this end we extracted mRNA from the developing murine brain (E10.5, E12.5, E14.5, E16.5, E18.5, P0, and P6), generated cDNA, and performed qPCR analysis. We observed that Mast1 expression begins at E12.5, peaks at E16.5, and decreases postnatally (Figure 2B) . Consistent with this result, qPCR analysis of human fetal brain cDNA showed moderate expression of MAST1 at gestation weeks 13 and 22 (Figure 2A ). To determine which cells express Mast1, we performed immunohistochemistry on the murine cortex at E12.5, E14.5, E16.5, and P0 (n = 3). We used a commercially available Mast1 antibody, having validated its specificity employing a Mast1 knockout (KO) animal ( Figures S3B-S3D ). We observed staining in the developing cortical plate and intermediate zone at these time points ( Figures 2C-2F ). Further analysis at E14.5 and E16.5 showed that Mast1 is located in the cytoplasm in Tuj-positive post-mitotic neurons but is largely absent from Sox2-positive progenitors and Tbr2-positive intermediate progenitors (Figures 2S-2AP) (n = 3). This expression pattern is mirrored in human cerebral organoids that were cultured for 64 days, where we again observed co-localization with post-mitotic markers (Figures S2A-S2F) (n = 10 organoids) (Lancaster et al., 2013) . Immunostaining on P0 mouse brain sections showed that Mast1 is present in Tuj-positive corpus callosal fibers that cross the midline (n = 3) ( Figures S2G-S2L ). To gain further insight into the subcellular localization of Mast1, we cultured primary P0 cortical neurons and P7 cerebellar granule neurons and performed immunostaining. We again validated the specificity of our Mast1 antibody for cell culture experiments employing a Mast1 KO animal ( Figure S2S -T). We performed double staining with antisera specific for the axonal marker Tau or the dendritic marker Map2 (Kosik and Finch, 1987) . We observed Mast1 staining throughout the soma, as well as in dendritic and axonal compartments in cortical neurons ( Figures 2G-2R , n = 5) and in cerebellar granule neurons qPCR analysis of Mast1 expression in the adult mouse showed that its expression persists in all brain regions (albeit at much lower levels) and that it is present in the testes, liver, and spleen at very low levels (n = 3) ( Figure S2U ). These results are consistent with expression data that are available through online databases (e.g., Allen Brain Atlas, GTEx) (GTEx Consortium, 2013; Morris et al., 2010) . Taken together, these data show that Mast1 is predominantly expressed in post-mitotic neurons in the developing nervous system.
An Enlarged Corpus Callosum in a L278Del Mast1
Mouse Model
To investigate the effect of Mast1 mutations in vivo, we exploited the power of the CRISPR-Cas9 genome editing system to generate a Mast1 KO mouse and a Mast1 L278del (L278del) mouse employing guide RNAs targeted to exon 8 ( Figure S3A ) (Wang et al., 2013) . We decided to recapitulate the mutation identified in patient P3 because of the striking callosal, cortical, and cerebellar phenotypes. As homozygous L278del/del animals die shortly after birth, we focused our initial analysis on ho- resonance imaging (MRI) analysis confirmed an increased corpus callosum volume in L278del/+ animals ( Figure 3H ; n = 3; +/+ versus L278del/+; p < 0.05) and revealed that the thickening was most prominent in the rostral regions encompassing the genu and the mid-body ( Figures 3F and 3G) . The enlarged corpus callosum was also present in L278/del mice aged 10 days ( Figures S3K-S3M ; n = 5; +/+ versus L278del/+; p < 0.05). While off-target mutations in Cas9-modified mice are rare (Iyer et al., 2015) , we confirmed that this phenotype was not due to a linked mutation by undertaking whole-exome sequencing for our L278del/+ mouse line. We identified no other non-synonymous mutations on chromosome 8 in this line (Table  S3 ). Moreover, we generated a second independent L278del mouse line and once again observed an enlarged corpus callosum ( Figures S3H-S3J ; +/+ versus L278del/+_Line#7; n = 3; p < 0.01).
We then asked whether the increase in the thickness of the corpus callosum of the L278del/+ mice was due to an increase in the thickness of myelinated axons. In light of our MRI studies, we focused our analysis on the midbody of the corpus callosum, where we observe the most pronounced phenotype in L278del/+ mutants (bregma À0.10). The corpus callosum of adult animals was microdissected, samples were stained to enable clear visualization of myelinated neurons crossing the midline, and images captured at high resolution (8,9003) with transmission electron microscopy ( Figures 3I and 3J) (Sturrock, 1980; West et al., 2015) . We observed no significant difference in either myelin thickness ( Figure 3K ; n = 5; n > 500 axons per animal; +/+ versus L278del/+; p > 0.1) or axonal caliber ( Figure 3L ; n = 5; n > 1500 axons per animal; +/+ versus L278del/+; p > 0.1) when comparing littermate controls with L278del/+ animals. An analysis of the distribution of axon calibers in L278del/+ animals again revealed no significant difference in comparison to littermate controls (n = 5; +/+ versus L278del/+; p > 0.1 for all bins) ( Figure S3U ). Reflecting this, an assessment of the G-ratio (axonal diameter/total fiber diameter), revealed no significant difference between genotypes (n = 5, n > 300 fibers animal, +/+ versus L278del/+; p > 0.1) ( Figure S3N ) .
Given these results, we asked whether more myelinated axons might cross the midline in L278del/+ animals. To assess this, TEM images were acquired at a magnification of 7103 along the dorso-ventral axis of the corpus callosum. These images (10-12 per animal) were tiled, resulting in a single image that encompassed the entire cross-section of the corpus callosum. A box 30 mm wide was overlaid onto the structure, and the total number of myelinated axons was counted manually (Figures 3M  and 3N ). Statistical analysis revealed a significant increase in the number of myelinated axons within that box in L278del/+ animals in comparison to littermate controls ( Figure 3O ; n = 5 animals per genotype, n = 3 images per animal, +/+ versus L278del/+; p < 0.01). Finally, we counted the number of Olig2-positive oligodendrocyctes and GFAP-positive astrocyctes in a box of fixed width that was overlaid onto coronal sections of the corpus callosum ( Figures S3O-S3R ). This revealed that in L278del/+ animals there are more oligodendrocytes and astrocyctes in comparison to wild-type controls (n = 5; +/+ versus L278del/+; Olig2, p < 0.05; GFAP, p < 0.05) ( Figures S3S and S3V ). There was, however, no significant difference in the density of these cell types when comparing genotypes (n = 5; +/+ versus L278del/+; Olig2, p > 0.5; GFAP, p > 0.05) ( Figures S3T and  S3W) . Taken together, these data show that our L278del/+ mouse model recapitulates the enlarged corpus callosum observed in affected patients, which we attribute to an increase in the number of myelinated axons crossing the midline.
Cortical and Cerebellar Hypoplasia in the L278del Mast1
We extended our analysis of the L278del and KO mouse lines to the cortex and cerebellum, which are consistently affected in our MAST1 patient cohort. MRI volumetric analysis of adult animals revealed an overall reduction in cortical volume in L278del heterozygotes (Figures 4A-4C; n = 3; +/+ versus L278del/+; p < 0.05). We confirmed this finding by undertaking Nissl and NeuN staining, where we observed a significant reduction in cortical thickness in L278del animals that was most pronounced in caudal regions (bregma À1.82 mm; Nissl [Figures 4D-4F]: n = 5, +/+ versus L278del/+, p < 0.001; NeuN [Figures S4A-S4D]: n = 5; +/+ versus L278del/+; p < 0.0001). We did observe a reduction in cortical thickness in the rostral motor cortex in L278del heterozygotes (bregma 0.86 mm); however, this was not statistically significant ( Figures S4E-S4G , n = 5; +/+ versus L278del/+; p > 0.1). We assessed the thickness of the cortical layers in the affected caudal regions in L278del heterozygotes and littermate controls. We observed a significant reduction in the thickness of layer 5, marked by the transcription factor Er81 (Figures 4J-4L; n = 5; +/+ versus L278del/+; p < 0.01). We did not observe a significant difference in the thickness of MRI volumetric analysis of the cerebellum revealed a severe reduction in L278del heterozygotes (Figures 5A-5C; n = 3; +/+ versus L278del/+; p < 0.001). Nissl staining as well as NeuN and calbindin immunohistochemistry showed that the foliation and lamination of the cerebellum in L278del heterozygotes was comparable to wild types; however, the granule and the molecular cell layer appeared thinner in mutants ( Figures 5D-5I) . We calculated the density of granule cells as well as the linear density of Purkinje cells, allowing us to estimate the total number of these cell types in midsagittal sections. While the density of both cell types was similar in L278del mutants in comparison to littermate controls ( Figures S5A and S5B) , we observed a significant reduction in the total number of granule cells per section ( Figure 5J ; n = 5; +/+ versus L278del/+; p < 0.05). We also observed a reduction in the total number of Purkinje cells per section, but this reduction was not statistically significant (Figure 5K ; n = 5; +/+ versus L278del/+; p > 0.5). Volumetric analysis of the colliculi, putamen, thalamus, and olfactory bulbs revealed no significant difference between wild-type littermates and L278del heterozygotes ( Figure S5C ; n = 3; +/+ versus L278del/+; p > 0.5 for all regions). There was a reduction in the volume of the hippocampus in L278del heterozygotes, but this difference was not statistically significant ( Figure S5C ; n = 3; +/+ versus L278del/+; p = 0.34).
Neuronal Apoptosis in the L278del Mast1 Mouse Model
To determine if the smaller cortex and cerebellum in our L278del mutant mice is a result of neuronal cell death during development, we performed an activated caspase-3 staining. We detected a dose-dependent increase in the number of apoptotic cells in the P0 cortex of wild-type versus heterozygous and homozygous L278del mice ( Figures 4P-4U , 4Y, and S4 AB; n = 5; +/+ versus L287del/+ p < 0.01; +/+ versus L278del/del p < 0.0001; L278del/+ versus L278del/del p < 0.001). Consistent with our anatomical analysis of adult animals, we found that apoptosis was more severe in the caudal regions of the P0 cortex in the L278del/+ and L278del/del animals ( Figure S4V; To ascertain whether this cell death is associated with intrinsic suicide pathways, we stained P0 cortical sections with sera that target activated caspase-9, an upstream regulator of caspase-3 that is associated with mitochondrial mediated apoptosis (Hyman and Yuan, 2012) . We observed a dose-dependent increase in the number of activated caspase-9-positive cells in the cortex of heterozygous and homozygous L278del mice ( Figures 4V-4X and 4Z; n = 5; +/+ versus 278del/+ p < 0.05; +/+ versus L278del/ del p < 0.0001; L278del/+ versus L278del/del p < 0.01). Intriguingly, this was not associated with the upregulation of the tumor suppressor p53 (Figures S4AA-S4AF ), which has been associated with a range of stressful cellular events including DNA damage, defects in cell cycle progression, as well as oxidative and nutritional stress (Szybi nska and Le sniak, 2017). Taken together, these data show that the L278del mutation results in a hypoplastic cortex and cerebellum, a phenotype that is associated with neuronal apoptosis mediated by activated caspases 3 and 9, but not p53 upregulation.
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The L278 Microdeletion Alters Mast1/2/3 Protein Levels but Not the PI3K/AKT3/mTOR Pathway Next, we exploited these mouse models to investigate the underlying molecular impairment associated with MAST1 mutations. Western blot analysis of P0 brain lysates showed a complete absence of Mast1 protein in KO animals (n = 6), with an unexpected dose-dependent reduction in Mast1 levels in the L278del line ( Figure 6A -D; n = 4, Mast1: +/+ versus L278del/+ p < 0.0001; +/+ versus L278del/Ldel p < 0.0001). This absence of protein in the Mast1 KO animals correlates with a dramatic reduction in mRNA levels, but this is not the case in L278del mice, where Mast1 transcript levels are statistically similar in +/+, L278del/+, and L278del/del animals ( Figures S6A and  S6D ). We assessed whether the reduction in Mast1 protein levels would influence the levels of other MAST family members. Relying on western blot analysis, we observed a striking reduction in the levels of Mast2 and Mast3 in our L278del animals ( Figures 6A and 6B ; n = 4; Mast2: +/+ versus L278del/+ p < 0.0001; +/+ versus L278del/del p < 0.0001; Mast3: +/+ versus L278del/+ p < 0.0001; +/+ versus L278del/del p < 0.0001). This was not attributable to changes in the mRNA levels of Mast2 and Mast3, which were similar in +/+, L278del/+, and L278del/ del animals ( Figures S6B and S6C) . In contrast, in our Mast1
KO animals we observed a signficant increase in the levels of Mast2 and Mast3 (Mast2: +/+ versus KO p < 0.0001; Mast3: +/+ versus KO p < 0.001), again with no change in the mRNA levels ( Figures S6E and S6F) . These data imply that the L278del mutation in Mast1 acts by a dominant-negative mode of action, whereas a form of post-transcriptional compensation occurs in the Mast1 KO line. Finally, as previous studies have implicated activation of the PI3K/AKT3/mTOR pathway in corpus callosum hyperplasia associated with megalencephaly, we assessed the phosphorylation state of AKT and rpS6 in our L278del mice ( Figure 6E) (Broix et al., 2016; Poduri et al., 2012; Riviè re et al., 2012; Terrone et al., 2016) . We observed no difference in the levels of p-AKT S473 and p-rpS6 S240/244 when comparing heterozygous and homozygous L278del brain lysates with wild-type controls ( Figure 6F ; n = 5 animals; +/+ versus L278del/+ AKT p > 0.5; +/+ versus L278del/del AKT p > 0.5; L278del/+ versus L278del/del AKT p > 0.5; +/+ versus L278del/+ rpS6 p > 0.5; +/+ versus L278del/ del rpS6 p > 0.5; L278del/+ versus L278del/del rpS6 p > 0.5).
DISCUSSION
Here, we report that de novo mutations in MAST1 cause MCC-CH-CM, a disease characterized by a striking enlargement of the corpus callosum, cerebellar hypoplasia, and cortical malformations. For patients with this constellation of phenotypes, mutations in MAST1 appear to be the primary genetic cause, as we observed MAST1 variants in 6 of the 7 patients that we studied. We have shown that MAST1 is expressed predominantly in postmitotic neurons in the developing nervous system, and that it is present in the soma as well as dendritic and axonal compartments. We demonstrate that a L278del mouse line recapitulates the enlarged corpus callosum and cerebellar hypoplasia observed in patients, while the Mast1 KO line lacks any morphological defects. We report extensive cortical apoptosis in our L278del mice that is mediated by activated caspases 3 and 9, but not p53 upregulation. We report that this apoptosis varies along the rostro-caudal axis of the cortex, being most severe in caudal regions where the enlarged corpus callosum is least pronounced. Our results show that, unlike other syndromes associated with an enlarged corpus callosum, activation of the PI3K/AKT3/mTOR pathway does not appear to be the underlying pathogenic driver (Terrone et al., 2016) .
What molecular mechanism underlies MCC-CH-CM? We have shown that MAST1 binds to microtubules in a MAP-dependent manner, but this binding is only altered in the case of the K276del mutation. It therefore seems unlikely that alterations in microtubule affinity cause the spectrum of phenotypes we observe in patients with MCC-CH-CM. Analysis of our L278del mouse model has shown a dramatic reduction in the levels of Mast2 and Mast3 protein. This result suggests that pathogenic microdeletions in Mast1 act by a dominant-negative mechanism and that the Mast proteins (like other AGC kinases) may physically interact (Leroux et al., 2018) . Notably, three of the deletions detected in patients were located in the domain of unknown function (DUF1608), which adopts a 4-helix bundle structure in solution (PDB: 2M9X). Since the helices pack together to form a hydrophobic core, it is expected that the Glu194del, Lys276del, and Leu278del microdeletions would disrupt this structure by changing the register of the a helices. It is therefore conceivable that these MAST1 microdeletions exert a dominantnegative effect by titrating out functional endogenous MAST proteins and/or targeting them for degradation. The consequence of the reduction in Mast1/2/3 levels is likely to be complex, influencing the phosphorylation of multiple targets. Little is known of the targets of the MAST family; however, Andrade and colleagues have recently shown that in mature dopaminergic neurons in the striatum, MAST3 phosphorylates ARPP-16 at Ser46, which in turn inhibits the serine-threonine phosphatase PP2A (Andrade et al., 2017) . Mast2 has been reported to interact with b2-syntrophin, but its targets are otherwise undefined (Lumeng et al., 1999) . Future experiments that define and validate the targets and binding partners of the MAST family in the developing brain will provide valuable insight on this front. Why do our L278del mice have a thicker corpus callosum? We report that our L278del mice present with an enlarged corpus callosum that is most severe in the midbody and genu and manifests despite an increase in cortical apoptosis. Electron microscopic analysis has revealed that this phenotype is not attributable to an increase in the caliber of myelinated neurons, nor to the thickness of the myelin sheath itself, but is associated with an increase in the number of axons that project to the contralateral hemisphere. Such a phenotype may result from:
(1) an increase in the branching of callosal fibers, (2) the formation of multiple axons originating from the soma of projection neurons, or (3) a change in the fate of differentiating neurons during embryogenesis resulting in an increase in the number of callosal projection neurons at the expense of sub-cortical projection neurons (Baranek et al., 2012; Britanova et al., 2008) .
Finally, we report the presence of de novo MAST1 substitutions in patients with severe autism and microcephaly. Notably, a de novo P500L mutation in MAST1 has also been reported in a patient presenting with cerebral palsy (McMichael et al., 2015) . This suggests that mutations in MAST1 give rise to a spectrum of neurodevelopmental diseases. Unlike those mutations that we describe in patients with MCC-CH-CM, these variants are all substitutions, which might account for the different clinical phenotypes. At this stage we are not able to comment on the functional effect of these substitutions, or on the impact of the $750 coding variants reported in the ExAC control genome database. In light of our work, it is conceivable that mutations in MAST2 and MAST3, both of which are expressed in the developing and adult brain, might also result in neurological disease (Garland et al., 2008) . In conclusion, we have defined the genetic lesion that causes MCC-CH-CM and revealed the importance of the MAST family in global brain development.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Mice were maintained on a 12:12 light dark cycle and food was available ad libitum. Mice of ages E10.5, E12.5, E14.5, E16.5, P0, P6, 8-10 weeks were used in this study. Animals were not subject to randomization and allocated to experimental groups according to their genotypes as littermates regardless of the sex. For experiments with mice of ages E10.5, E12.5, E14.5, E16.5, P0, P6 the sex was not determined. For generating CRISPR mouse lines, female BL6/CBA F1 mice were used, whereas all backcrosses were performed using C57/BL6 mice to the 7th generation. All procedures were carried out according to legal requirements and covered by an approved license (M58/006093/2011/14).
Human studies
Informed consent was obtained from all patients included in this study. Details of each patient and the condition is provided in Tables 1 and S1. This study was conducted within approved ethical frameworks University of Oxford (08/MRE09/55); Stanford University Institutional Review Board (28362); University of Alabama at Birmingham (X130201001); and at the Seattle Children's Research Institute (IRB protocol #13291); and by the Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen (NL36191.091.11).
Cell Lines, primary cultures, microbe strains For generating cerebral organoids, feeder free H9 human embryonic stem cells (ESCs) were obtained from Wicell (WA09), having a normal karyotype, female sex, and no contaminants. These cells were maintained using the commercially available mTESR media (Stem cell technologies #05850) at 37 C with 5% CO 2 levels. These cells were not authenticated. Primary cell cultures were generated from P0 and P7 cortex or cerebellum. The sex of these pups was not determined. The primary neurons were cultured in Neurobasal media with B27, Penstrep and L-glutamine supplements at 37 C with 5% CO 2 levels. The Escherichia coli DH5alpha strain was used for cloning purposes.
METHOD DETAILS
Exome Sequencing
Patients with structural brain phenotypes and their parents were recruited in accordance with existing ethical frameworks and internal review boards. DNA from blood was extracted using standard methods and subject to exome sequencing. We exploited capture arrays (such as the Agilent Human All exon 50Mb array) to capture exonic genomic DNA, which was then subject to next generation paired end sequencing (Illumina). Bioinformatic filtering employed platforms such as the Genome Analysis Toolkit (GATK), and excluded variants with a population frequency greater than 1%. For this purpose, we relied on available genomic databases including dbSNP and the 1000 Genomes server. Sanger sequencing was employed to confirm any putative de novo variants. This study was conducted within an approved ethical framework (08/MRE09/55). For mouse exome sequencing genomic DNA was extracted from the tails of BL6J, CBA, and L278del mice and then subjected to Illumina library preparation and captured on the Agilent SureSelect mouse (51Mb) array. The samples were sequenced on an Illumina HiSeq2500 with 100-125 nucleotides paired-end reads followed by data quality analysis using FASTQC. Reads were mapped to the mouse genome (GRCm38, mm10) using BWA (Li and Durbin, 2010) . The BAM files were used as an input to UnifiedGenotyper module from the GATK-lite toolkit (v2.3). (McKenna et al., 2010) Variants were called and dbSNP variants were used as known sites, according to GATK Best Practices recommendations (DePristo et al., 2011) . Finally, Variants were annotated by SnpEff v4.1 (Cingolani et al., 2012) . Sanger sequencing was employed to confirm putative de novo variants on chromosome 8, potentially linked to the L278del mutation (Table S2 ).
